Ys Biopharma Co Stock Piotroski F Score

YS Stock   1.02  0.11  12.09%   
This module uses fundamental data of YS Biopharma to approximate its Piotroski F score. YS Biopharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of YS Biopharma Co. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about YS Biopharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out YS Biopharma Altman Z Score, YS Biopharma Correlation, YS Biopharma Valuation, as well as analyze YS Biopharma Alpha and Beta and YS Biopharma Hype Analysis.
  
At this time, YS Biopharma's Net Debt is comparatively stable compared to the past year. Debt To Equity is likely to gain to 0.65 in 2024, whereas Long Term Debt is likely to drop slightly above 201.2 M in 2024. At this time, YS Biopharma's Intangibles To Total Assets are comparatively stable compared to the past year. Current Ratio is likely to gain to 1.95 in 2024, whereas Free Cash Flow Yield is likely to drop (0.28) in 2024.
At this time, it appears that YS Biopharma's Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Unavailable
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Decreasing

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

Lower Leverage

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

YS Biopharma Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to YS Biopharma is to make sure YS Biopharma is not a subject of accounting manipulations and runs a healthy internal audit department. So, if YS Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if YS Biopharma's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.260.36
Way Down
Slightly volatile
Gross Profit Margin0.620.7
Fairly Down
Slightly volatile
Total Current Liabilities542.6 M757.6 M
Way Down
Slightly volatile
Non Current Liabilities Total284.3 M299.3 M
Notably Down
Slightly volatile
Total Assets1.6 BB
Significantly Down
Slightly volatile
Total Current Assets929.1 M1.2 B
Significantly Down
Slightly volatile

YS Biopharma F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between YS Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards YS Biopharma in a much-optimized way.

About YS Biopharma Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Pretax Profit Margin

(0.19)

At this time, YS Biopharma's Pretax Profit Margin is comparatively stable compared to the past year.

About YS Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with YS Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if YS Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in YS Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against YS Biopharma Stock

  0.78VRDN Viridian TherapeuticsPairCorr
  0.78LRMR Larimar TherapeuticsPairCorr
  0.74KROS Keros TherapeuticsInc Earnings Call This WeekPairCorr
  0.69JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr
  0.67MRSN Mersana TherapeuticsPairCorr
The ability to find closely correlated positions to YS Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace YS Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back YS Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling YS Biopharma Co to buy it.
The correlation of YS Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as YS Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if YS Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for YS Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out YS Biopharma Altman Z Score, YS Biopharma Correlation, YS Biopharma Valuation, as well as analyze YS Biopharma Alpha and Beta and YS Biopharma Hype Analysis.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
9.461
Earnings Share
(0.57)
Revenue Per Share
4.67
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.10)
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.